April 10, 2024
Reporter, Morning Rounds Writer
Good morning. David Ropeik has been writing about what we're afraid of for years, reminding us how irrational we can be to fear the exotic rather than the familiar danger. Today, in a First Opinion, he tells us the fear of cancer can be as deadly as the disease itself, even for experts who you'd think would know better.

cancer

Cancer vaccines are picking up speed
GettyImages-1236774601

Patrick Hertzog/AFP via Getty Images

Cancer vaccines may have turned a corner. After a decade of challenges, researchers from industry and academia presented a slew of promising early data this week at the American Association for Cancer Research annual meeting in San Diego. Results from two early-stage clinical trials hint at when cancer vaccines may become important: in preventing or lowering the risk of relapse after surgery. One is an early-phase trial of a personalized neoantigen vaccine from the French biotech Transgene for head and neck cancer. The other trial is of a BioNTech and Genentech cancer vaccine for pancreatic cancer patients after surgery.

“If you’ve actually removed the majority of the tumor and you stimulate immunity, it can provide long-term immune-surveillance — that is a setting that makes a lot of sense,” said Catherine Wu of the Dana-Farber Cancer Institute. “If you give it in a relapse setting, it’s just a higher hurdle to overcome.” STAT’s Angus Chen explains.


insurance

MassMutual offers free genetic testing for members

A major life insurer is testing the waters for genetic testing its customers, venturing into a zone long considered a minefield. To further its goal of keeping its members alive longer, MassMutual is offering many of its 4.2 million policyholders free genetic risk assessments for common conditions, including heart disease, type 2 diabetes, and breast cancer. The pilot project’s purpose is to inspire members to take action to lower their risk once they are alerted to it.

“I think what’s remarkable about this story is that in some ways it’s taken so long,” said Robert Green, a medical geneticist and professor at Harvard Medical School. Privacy concerns are high on the list of barriers. MassMutual says it will neither see individual risk scores nor will it know who took the tests, so the scores won’t affect “current premiums or policies.” STAT’s Tara Bannow has more, including skepticism on that score as well as questions about the conditions chosen.


drug pricing

Here's how you defend a 486% price hike 

Before you see shades of "pharma bro" Martin Shkreli, the maker of an injectable eye treatment wants you to consider why a 486% price hike might be reasonable. Unlike list prices jumping by triple-digit percentages when a company simply changed hands (see Valeant Pharmaceuticals), the price of Triesence is going up from $161 to $944 because Harrow, its manufacturer, is investing in upgraded production to bring an "underpriced" drug back to market. “It was a Model T vehicle in a Tesla Model S world,” CEO Mark Baum told STAT’s Ed Silverman. 

The medication, typically injected once or twice, is approved for treating ocular inflammatory conditions caused by disease or injury. People covered by Medicare Part B might have to pay 20% of the cost. “Paying $200 or $250 isn’t something you’re likely to be excited about,” said Vanderbilt’s Stacie Dusetzina. “I think most people will probably think it’s worth that amount of money if it’s going to help them see.” Read more.



closer look

Opinion: How fear of cancer can kill, tooGettyImages-1237273485

Pascal Pochard-Casabianca/AFP via Getty Images 

Cancer is a cruel killer, First Opinion writer David Ropeik reminds us, one whose name people were afraid to speak not too many generations ago and one that still haunts us today. There’s good reason to fear cancer, the second leading cause of death (behind heart disease) in the U.S., but fear of cancer can also be deadly. That fear, or cancer-phobia, as journalist and author Ropeik calls it, keeps people from seeing their doctors or getting screening tests that might improve their chances if they do in fact have cancer.

Even after a daunting diagnosis of lung cancer, people in a recent study delayed coming in for treatment by a median of more than three months. Lung cancer is not the exception, and even a world-renowned cancer expert fearing prostate cancer fell into the avoidance camp. “The War on Cancer badly needs another front, to battle the damage that too much fear of this dread disease can generate,” Ropeik concludes. Read more.


covid

Current long Covid cases settling at 1 of 10 infected

around-3-in-10-adults-who-have-had-covid-report-getting-long-covid

Long Covid rates have begun to flatten, a new KFF analysis says, leveling off at about 1 in 10 people infected with Covid-19. That’s lower than the about 3 in 10 people surveyed who said they’d ever had the brain fog, fatigue, and other lingering symptoms after their initial illness. Some people are recovering, the researchers say, but the need for diagnosis and treatment remains urgent. For context, the estimated 17 million adults now living with long Covid is roughly equivalent to the number of people who have cancer or coronary artery disease, the report says.

Most people with long Covid say it limits their activity, including employment and paying for food, rent, and other basic needs. “Rates of long Covid have remained relatively consistent for the last year, suggesting they may persist indefinitely unless new forms of prevention or treatment are discovered,” the analysis concludes.


health care

Nurses explain why they’ve left the profession

The nursing shortage is not new; it just got worse during the pandemic. Studies have documented the toll on health care providers from Covid-19, citing many nurses’ intentions to exit the profession. A new paper in JAMA Network Open surveyed nearly 8,000 registered nurses who had actually left to ask why. Most were retiring, but between 2018 and 2021, burnout, insufficient staffing, family obligations, Covid-19 concerns, and unsafe working conditions were also behind decisions to pursue employment outside health care. Among retirees, 41% said their retirements were not planned. 

Some comments from the survey participants: 

  • “I would have worked another year or two if we had safe staffing ratios.”
  • “Patients are sicker and more complex than ever. … I was constantly voicing concerns for patient safety. ... Can I get another nursing job? Absolutely. … Do I want to? Not really.”
  • “I did not want to leave my team, peers, and patients, but the unsupported weight created by the hospital system was too much to [bear] any longer."

More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • NCI director expresses optimism about next era of cancer research, despite shrinking budget and brain drain, STAT
  • Philips, maker of millions of defective sleep apnea machines, ordered to overhaul manufacturing, Associated Press
  • They were bitter rivals. Then one of them needed a kidney, Washington Post
  • Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells, STAT
  • In the womb, a brother's hormones can shape a sister's future, NPR
  • New WIC rules include more money for fruits and veggies. They also expand food choices, Associated Press


Thanks for reading! More tomorrow,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.